The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis

Background. The recommended therapy for patients with chronic hepatitis C (CHC), genotype 1, who have cirrhosis and have failed prior therapy is 12 weeks of sofosbuvir (SOF), ledipasvir (LDV), and ribavirin (RBV). This recommendation is based on expert opinion, and the efficacy of 12 weeks of SOF/LD...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Can J Gastroenterol Hepatol
Päätekijät: Stokes, William, Fenton, Carol, Clement, Fiona, James, Matthew, Ronksley, Paul, Tang, Karen L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi 2017
Aiheet:
Review Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358456/
https://ncbi.nlm.nih.gov/pubmed/28367429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6468309
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia